HOLX

Hologic, Inc. develops, manufactures, and supplies medical imaging systems, diagnostic products, and surgical products focused primarily on women's health. Headquartered in Marlborough, Massachusetts, the company operates through four main divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its portfolio includes 3D mammography systems (Genius), molecular diagnostic assays (including the Panther platform), minimally invasive surgical devices (MyoSure and NovaSure), and bone densitometry systems. Hologic serves hospitals, clinics, laboratories, and healthcare providers across more than 160 countries worldwide. The company employs approximately 6,500 people globally and generates annual revenue exceeding $4 billion. Hologic holds leading market positions in breast imaging and cervical cancer screening, with its ThinPrep Pap test and Aptima molecular diagnostics serving as diagnostic standards. The acquisition of Cynosure in 2017 expanded its medical aesthetics capabilities, while the 2020 purchase of Biotheranostics strengthened its precision oncology offerings. Recent strategic focus includes advancing its BioZorb surgical marker platform, expanding international markets for its Genius 3D mammography technology, and developing next-generation molecular diagnostic solutions. The company maintains substantial R&D investments and holds thousands of patents protecting its proprietary technologies. Hologic's COVID-19 diagnostic tests became significant revenue contributors during the pandemic, though the company continues diversifying its revenue base across its core women's health franchises.